Listed by the USPTO as STEVENS, MARK V
Tech Center 1600 • Art Units: 1600 1613 1646 1655
This examiner grants 66% of resolved cases
STEVENS, MARK V is assigned to technology center 1600 and art unit 1600. The profile reports 881 resolved cases, an allowance rate of 65.5%, and an interview lift of 41.4%. The median time to allowance is 977 days. The extensive case record supports meaningful historical analysis, and the interview measure provides a substantial additional factor for planning prosecution communications.
The listed companies are Antecip Bioventures Ii LLC, The Regents of the University of Michigan, and The Procter & Gamble Company. The listed firms are HESLIN ROTHENBERG FARLEY & MESITI PC, BIRCH STEWART KOLASCH & BIRCH, LLP, and Casimir Jones, S.C. Counsel can combine these stakeholder patterns with the outcome and timing data when developing matter-specific strategy.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18911341 | ORAL CARE COMPOSITIONS COMPRISING DICARBOXYLIC ACID | Non-Final OA | The Procter & Gamble Company |
| 17694270 | DELIVERY OF SURFACTANT SOLUBLE ANTI-DANDRUFF AGENT | Non-Final OA | The Procter & Gamble Company |
| 18293204 | POLYMER NANOPARTICLES VIA CONDENSED DROPLET POLYMERIZATION | Final Rejection | CORNELL UNIVERSITY |
| 18570690 | BIOMATERIALS COATING FOR ON-DEMAND BACTERIA DELIVERY AND METHOD TO TREAT COLITIS AND IRRITABLE BOWEL SYNDROME | Final Rejection | Wisconsin Alumni Research Foundation |
| 18169695 | HEMOSTATIC NANOPARTICLES FOR THE TREATMENT OF NON-COMPRESSIBLE HEMORRHAGE AND INTERNAL BLEEDING | Final Rejection | The General Hospital Corporation |
| 19110125 | USE OF AN ALKYLETHER SULFATE FOR IMPROVING THE EFFICACY OF HERBICIDES | Non-Final OA | BASF SE |
| 18838825 | MODIFIED RELEASE VALPROIC ACID SOFTGEL CAPSULE | Final Rejection | R.P. SCHERER TECHNOLOGIES, LLC |
| 18880365 | COMPOSITION FOR INDUCING LIGAMENTIZATION OF TENDON, COMPRISING ANTERIOR CRUCIATE LIGAMENT-DERIVED STEM CELLS | Non-Final OA | IUCF-HYU (INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY) |
| 18738288 | Zinc Phosphate Complex | Final Rejection | Colgate-Palmolive Company |
| 19104001 | SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLES FOR IMMUNOTHERAPY | Non-Final OA | BRAIN & BEYONDS CO., LTD. |
| 18847701 | HAIR CONDITIONER FORMULATION | Non-Final OA | Dow Silicones Corporation |
| 18851376 | Stable Dentrifice Compositions With High Sodium Bicarbonate Loading | Non-Final OA | Lubrizol Advanced Materials, Inc. |
| 18747164 | MICROWAVE ASSISTED EXTRACTION OF ESSENTIAL OILS FROM PLANT BIOMASS | Final Rejection | Firmenich SA |
| 18778471 | POLYMERSOME NANOPARTICLES EXHAUSTING INTRACELLUAR AMINO ACID FOR CANCER THERAPY AND METHODS THEREOF | Final Rejection | THE UNIVERSITY OF HONG KONG |
| 18198471 | Multivitamin | Non-Final OA | Individual inventor |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy65.5% of resolved applications examined by Mark V Stevens were allowed (881 resolved cases), compared with 36.5% across Art Unit 1600 over the last five years.
This examiner's interview lift is +41.4 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Mark V Stevens took 977 days on average from filing to allowance.
Mark V Stevens examines applications in Art Unit 1600 in Tech Center 1600 (Biotechnology & Pharmaceuticals).